Trusted by:

clients clients clients clients clients clients clients clients clients clients
Newswise:  Superspreader Fibrils Caught in the Act
Released: 28-Oct-2024 2:25 AM EDT
Superspreader Fibrils Caught in the Act
Empa, Swiss Federal Laboratories for Materials Science and Technology

In dementia diseases such as Alzheimer's, incorrectly folded proteins accumulate in the brain. Empa researchers have now resolved a particularly active species of protein fibrils with unprecedented precision. The formation of potentially toxic molecules on the surface of protein fibrils was studied from early to late stages spanning over a period of hours.

Newswise: A Single Thin Film Perfectly Absorbs All Electromagnetic Waves!
Released: 28-Oct-2024 12:00 AM EDT
A Single Thin Film Perfectly Absorbs All Electromagnetic Waves!
National Research Council of Science and Technology

The research team of Dr. Byeongjin Park and Dr. Sang Bok Lee at the Korea Institute of Materials Science (KIMS), has developed the world's first ultra-thin film composite material capable of absorbing over 99% of electromagnetic waves from various frequency bands (such as 5G/6G, WiFi, and autonomous driving radar) using a single material.

24-Oct-2024 6:25 AM EDT
Think You’ve Outgrown Your High School Years? When It Comes To Drinking, A New Study Suggests Maybe Not
Research Society on Alcoholism

Adults aged 35 to 60 are drinking at unprecedented rates, with those who binge drank in high school reporting more past 30-day high-risk drinking in midlife. And this link may be especially strong for women, according to a study just published in Alcohol: Clinical and Experimental Research Health. These trends are particularly concerning as health conditions, and biological processes common with aging put adults in midlife at greater health risk from alcohol use.

   
Newswise: Preclinical Studies Test Novel Gene Therapy for Treating IgA 
Nephropathy
18-Oct-2024 3:55 PM EDT
Preclinical Studies Test Novel Gene Therapy for Treating IgA Nephropathy
American Society of Nephrology (ASN)

IgA nephropathy is an autoimmune kidney disease, and complement, a component of the innate immune system, plays a role in the condition’s pathogenesis. Investigators have developed and tested a novel gene therapy that enters kidney cells and enables them to block complement activation. The research will be presented at ASN Kidney Week 2024 October 23– 27.

18-Oct-2024 3:50 PM EDT
Trial Assesses Antibody Therapy for Chronic Active Antibody-Mediated Kidney Transplant Rejection
American Society of Nephrology (ASN)

Chronic active antibody-mediated rejection (caAMR) is a common cause of allograft loss after transplantation, with no approved therapies. Clazakizumab, a monoclonal antibody that targets the inflammatory cytokine interleukin-6 (IL-6), stabilized kidney transplant recipients’ kidney function in a phase 2 trial. Investigators now have data from a phase 3 trial with clazakizumab. The findings from the Phase 3 IMAGINE trial, the largest placebo-controlled study in kidney transplant recipients with caAMR, will be presented at ASN Kidney Week 2024 October 23– 27.

18-Oct-2024 3:40 PM EDT
Researchers Test Imlifidase Enzyme Versus Plasma Exchange in Removing Donor-Specific Antibodies in Kidney Transplant Rejection Trial
American Society of Nephrology (ASN)

For kidney transplant recipients experiencing antibody-mediated rejection, the current standard of care involves removing donor-specific antibodies (DSAs) through plasmapheresis (PLEX)—a procedure that removes antibodies from the plasma portion of the blood. Results from a recent clinical trial reveal that an investigational drug called imlifidase, which cleaves and inactivates the type of antibodies that include DSAs, is more effective than PLEX. The research will be presented at ASN Kidney Week 2024 October 23–27.

18-Oct-2024 3:25 PM EDT
High-Impact Clinical Trials Generate Promising Results for Improving Kidney Health: Part 2
American Society of Nephrology (ASN)

The results of numerous high-impact phase 3 clinical trials that could affect kidney-related medical care will be presented in-person at ASN Kidney Week 2024 October 23–27.

18-Oct-2024 4:10 PM EDT
Do Certain Diabetes Drugs Increase the Risk of Acute Kidney Injury in Patients Taking Anti-Cancer Therapies?
American Society of Nephrology (ASN)

Glucagon-like peptide-1-receptor agonists (GLP-1RA) are medications that are increasingly prescribed for patients with type 2 diabetes and congestive heart failure. Reports of GLP-1RA–associated acute kidney injury (AKI) have emerged, but the risk of GLP-1RA–associated AKI among patients on anti-cancer drugs is unclear. Surprisingly, new research suggests that taking GLP-1RA is not associated with an increased risk of AKI in patients receiving anti-cancer therapies. The findings will be presented at ASN Kidney Week 2024 October 23– 27.

Newswise: Global, National, and Regional Trends in the Burden of
Chronic Kidney Disease among Women
18-Oct-2024 4:05 PM EDT
Global, National, and Regional Trends in the Burden of Chronic Kidney Disease among Women
American Society of Nephrology (ASN)

A recent analysis reveals that the number of chronic kidney disease (CKD) cases in women around the globe nearly tripled in the past three decades. Also, type 2 diabetes and hypertension were the leading causes of CKD-related deaths in women. The research will be presented at ASN Kidney Week 2024 October 23– 27.


close
1.48827